# Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

> **NCT06112340** · PHASE2,PHASE3 · RECRUITING · sponsor: **Sling Therapeutics, Inc.** · enrollment: 75 (estimated)

## Conditions studied

- Thyroid Eye Disease
- Graves Orbitopathy
- Endocrine System Diseases
- Eye Diseases
- Thyroid Associated Ophthalmopathy
- Graves Ophthalmopathy
- Thyroid Diseases
- Orbital Diseases
- Proptosis
- IGF1R
- Exophthalmos
- Hashimoto

## Interventions

- **DRUG:** linsitinib

## Key facts

- **NCT ID:** NCT06112340
- **Lead sponsor:** Sling Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-11
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2025-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06112340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06112340, "Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06112340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*